WebMD5h
New Guidance for Patients Taking GLP-1 Drugs Before Surgery
As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.
CBS19 News6h
Virginia Residents Are Using GLP-1s at a Below Average Rate
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
Jackson Progress-Argus7h
Georgia Has the 5th Highest Rate of GLP-1 Use in the Nation
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
KSJB AM8h
U.S. Obesity Market Analysis: Exploring Demographic & Geographic Disparities in GLP-1 Use
The first GLP-1 receptor agonist approved for obesity was liraglutide, marketed in the U.S. as Saxenda, in 2014. However, the ...
The Manhattan Mercury9h
Kansas Residents Are Using GLP-1s at an Above Average Rate
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
Iosco County News-Herald9h
Michigan Residents Are Using GLP-1s at the 6th Highest Rate in the Country
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
The Digital Courier9h
North Carolina Residents Are Using GLP-1s at a Slightly Above Average Rate
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
Southwest Iowa News9h
Iowa Has the 9th Highest Rate of GLP-1 Use in the Country
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
The Mountain Press9h
Tennessee Residents Are Using GLP-1s at the 13th Highest Rate in the Country
Medications such as semaglutide (branded as Ozempic and Wegovy) and tirzepatide (branded as Mounjaro and Zepbound) work by ...
Becker's Hospital Review9h
GLP-1, SGLT2s lower mortality risk by 74% in stroke survivors: Study
FDA approved medications included in the study were GLP-1s liraglutide, semaglutide and tirzepatide, and SGLT2s canagliflozin, dapagliflozin, empagliflozin and ertugliflozin. Here are five things to ...
Stoneham Independent10h
Massachusetts Residents Are Using GLP-1s at a Below Average Rate
Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
KTEN1d
Texas Has the 10th Lowest Rate of GLP-1 Use in the Nation
The first GLP-1 receptor agonist approved for obesity was liraglutide, marketed in the U.S. as Saxenda, in 2014. However, the ...